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We thank Dr Mehmood for his interest in our study in which we reported the cardioprotective 
effect of Orai1 inhibition after pressure overload in mice. Dr Mehmood nicely draws attention 
to the fact that several clinically used drugs inhibit Orai1-mediated Store-Operated Ca
2+
 Entry 
(SOCE) at therapeutically-achievable concentrations for leflunomide and teriflunomide or at 
higher dose for more SOCE-selective inhibitors such as lansoprazole, tolvaptan and 
roflumilast(1). We agree that this is potentially important and worthy of further consideration 
alongside other efforts to achieve benefit from Orai1 suppression. Various selective Orai1 
inhibitors have been developed, such as AnCoA4, CM2489 and CM4620, and clinical trials 
are on-going with such agents(2). While we are positive about Dr Mehmood’s perspective, we 
caution that potential concerns or limitations may need to be overcome. The potency of these 
drugs for inhibiting Orai1 and not Ca
2+
 signaling mediated by Transient Receptor Potential 
Canonical (TRPC) channels, for example, is required. Indeed, we identified JPIII as a potent 
and selective Orai1 inhibitor with improved physico-chemical characteristics for in vivo usage 
and showed that it possesses good efficacy, safety and pharmaceutical characteristics in mice. 
We therefore have proof-of-concept that in vivo selective Orai1 blockade with JPIII, without 
obvious systemic side effects, might provide a new efficient therapy by preserving normal 
Ca
2+
 handling and improving left ventricular function at adult stage even if increased cardiac 
mass occurs(3). By contrast, in vivo inhibition of TRPCs avoids the development of the 
cardiac hypertrophy(4). The concept of preserving or preventing pathological hypertrophy is 
still controversial and some reports showed that hypertrophy blockade may be detrimental(5). 
Therefore, we prefer to consider selective Orai1 inhibitors as potentially beneficial inotropic 
agents.  
We agree that efforts to repurpose clinically-used drugs for heart failure should be considered 
and we will progress such studies when we are in a position to do so after the Covid-19 
shutdown of our research facilities and when funding for such work is in place. This could be 
an important shortcut to new important therapies. In addition and in parallel, we encourage 
continued efforts to further understand Orai1 inhibition in the heart and its relevance to 
people. It is also important to properly understand the risks of potential adverse effects, 
especially given the associations of genetic disruption of ORAI1 with immune suppression. 
Key next steps include the need for extensive follow-up to confirm the benefit of in vivo 
Orai1 inhibition by JPIII and its new, further improved analogues, after pressure overload 
over long time periods and to test such agents in preclinical models of other heart failure 
etiologies like myocardial infarction and type I and II diabetes. We plan such studies and hope 
to report on them in the not-so-distant future. 
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